Literature DB >> 14522888

Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent.

Alastair H Kyle1, Lynsey A Huxham, Jennifer H E Baker, Helen E Burston, Andrew I Minchinton.   

Abstract

Bromodeoxyuridine (BrdUrd) is used extensively to measure the fraction of proliferating cells in tumors. Unlike endogenous markers of proliferation such as proliferating cell nuclear antigen (PCNA) and Ki-67, BrdUrd is exogenously administered and reaches the tumor via vasculature where it must then diffuse throughout the tissue to label S-phase cells. In this study, we examine the dose dependence of BrdUrd on the tumor distribution of labeled cells in histological sections. Analysis of the distribution of labeled cells in SiHa tumor xenografts showed that a dose between 400 and 1000 mg/kg was required to label cells 150 micro m from blood vessels, approaching the border of necrosis. Lower doses resulted in only the cells close to blood vessels being labeled. Interestingly, cells residing furthest from blood vessels still labeled albeit at half the level of cells situated proximal to the tumor vasculature. Results were compared with the penetration of BrdUrd seen in vitro using multilayered cell culture (MCC), a three-dimensional tissue culture model of solid tumors. Using MCC, an exposure of 100 micro M BrdUrd for 1 h was required for labeling of S-phase cells 150 micro m into the tissue, whereas cells adjacent to the edge of the tissue could be adequately labeled with just 5 micro M BrdUrd for 1 h. The area under the curve for a 100 mg/kg BrdUrd dose in mice was found to be approximately 30 micro M x h.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522888

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active β-catenin.

Authors:  E Lavergne; I Hendaoui; C Coulouarn; C Ribault; J Leseur; P-A Eliat; S Mebarki; A Corlu; B Clément; O Musso
Journal:  Oncogene       Date:  2010-09-20       Impact factor: 9.867

2.  Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.

Authors:  K K Y Cham; J H E Baker; K S Takhar; J A Flexman; M Q Wong; D A Owen; A Yung; P Kozlowski; S A Reinsberg; E M Chu; C-W A Chang; A K Buczkowski; S W Chung; C H Scudamore; A I Minchinton; D T T Yapp; S S W Ng
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

3.  Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids.

Authors:  Kimberley A Beaumont; Andrea Anfosso; Farzana Ahmed; Wolfgang Weninger; Nikolas K Haass
Journal:  J Vis Exp       Date:  2015-12-28       Impact factor: 1.355

4.  Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors.

Authors:  Sydney M Evans; Kevin W Jenkins; W Timothy Jenkins; Thomas Dilling; Kevin D Judy; Amy Schrlau; Alexander Judkins; Stephen M Hahn; Cameron J Koch
Journal:  Radiat Res       Date:  2008-12       Impact factor: 2.841

5.  The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

Authors:  Wieslawa H Dragowska; Sherry A Weppler; Mohammed A Qadir; Ling Yan Wong; Yannick Franssen; Jennifer H E Baker; Anita I Kapanen; Guido J J Kierkels; Dana Masin; Andrew I Minchinton; Karen A Gelmon; Marcel B Bally
Journal:  BMC Cancer       Date:  2011-10-01       Impact factor: 4.430

6.  Loss of the Notch effector RBPJ promotes tumorigenesis.

Authors:  Iva Kulic; Gordon Robertson; Linda Chang; Jennifer H E Baker; William W Lockwood; Winnie Mok; Megan Fuller; Michèle Fournier; Nelson Wong; Vennie Chou; Mark D Robinson; Hye-Jung Chun; Blake Gilks; Bettina Kempkes; Thomas A Thomson; Martin Hirst; Andrew I Minchinton; Wan L Lam; Steven Jones; Marco Marra; Aly Karsan
Journal:  J Exp Med       Date:  2014-12-15       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.